Table 2.
Adjusted Baseline Demographic and Clinical Characteristics of Study Population
| Baloxavir | Oseltamivir | Baloxavir | Laninamivir | Baloxavir | Zanamivir | ||||
|---|---|---|---|---|---|---|---|---|---|
| Characteristic | N = 240 341.4 | N = 238 657.8 | SMD | N = 227 633.9 | N = 227 618.3 | SMD | N = 164 892.3 | N = 163 701.7 | SMD |
| Age, years | |||||||||
| 1 to <2 | 4524.3 (1.9) | 4052.3 (1.7) | 0.01 | 108.0 (<0.1) | 105.5 (<0.1) | <0.01 | 107.0 (0.1) | 119.9 (0.1) | <0.01 |
| ≥2 to <5 | 20 581.4 (8.6) | 19 556.6 (8.2) | 0.01 | 1971.1 (0.9) | 1973.8 (0.9) | <0.01 | 1811.0 (1.1) | 1816.1 (1.1) | <0.01 |
| ≥5 to <18 | 72 693.4 (30.2) | 72 636.0 (30.4) | <0.01 | 75 151.6 (33.0) | 75 181.2 (33.0) | <0.01 | 57 299.9 (34.7) | 57 692.9 (35.2) | 0.01 |
| ≥18 to <65 | 139 660.2 (58.1) | 139 521.4 (58.5) | <0.01 | 147 656.6 (64.9) | 147 605.9 (64.8) | <0.01 | 103 719.4 (62.9) | 102 112.3 (62.4) | 0.01 |
| ≥65 | 2882.2 (1.2) | 2891.5 (1.2) | <0.01 | 2746.6 (1.2) | 2751.9 (1.2) | <0.01 | 1955.0 (1.2) | 1960.4 (1.2) | <0.01 |
| Sex | |||||||||
| Male | 134 638.5 (56.0) | 133 537.5 (56.0) | <0.01 | 127 490.0 (56.0) | 127 395.1 (56.0) | <0.01 | 92 370.5 (56.0) | 88 175.4 (53.9) | 0.04 |
| Female | 105 702.9 (44.0) | 105 120.3 (44.0) | <0.01 | 100 143.9 (44.0) | 100 223.2 (44.0) | <0.01 | 72 521.7 (44.0) | 75 526.3 (46.1) | 0.04 |
| Type of influenza | |||||||||
| A virus | 169 211.8 (70.4) | 168 300.2 (70.5) | <0.01 | 163 433.2 (71.8) | 163 420.6 (71.8) | <0.01 | 118 370.3 (71.8) | 116 356.6 (71.1) | 0.02 |
| B virus | 1683.5 (0.7) | 1657.8 (0.7) | <0.01 | 1693.1 (0.7) | 1686.2 (0.7) | <0.01 | 1182.8 (0.7) | 1203.3 (0.7) | <0.01 |
| A and B virus | 43.2 (<0.1) | 45.2 (<0.1) | <0.01 | 49.4 (<0.1) | 50.0 (<0.1) | <0.01 | 31.0 (<0.1) | 60.7 (<0.1) | 0.01 |
| Unknown | 69 402.8 (28.9) | 68 654.6 (28.8) | <0.01 | 62 458.2 (27.4) | 62 461.5 (27.4) | <0.01 | 45 308.2 (27.5) | 46 081.2 (28.1) | 0.01 |
| Steroid use | 758.1 (0.3) | 748.3 (0.3) | <0.01 | 771.1 (0.3) | 767.5 (0.3) | <0.01 | 517.5 (0.3) | 459.4 (0.3) | <0.01 |
| Dialysis use | 127.8 (0.1) | 129.9 (0.1) | <0.01 | 37.1 (<0.1) | 37.4 (<0.1) | <0.01 | 20.7 (<0.1) | 16.6 (<0.1) | <0.01 |
| Presence of the following comorbidities: | |||||||||
| Respiratory coinfectiona | 134 428.5 (55.9) | 134 519.8 (56.4) | <0.01 | 132 074.8 (58.0) | 131 973.9 (58.0) | <0.01 | 95 659.9 (58.0) | 94 354.7 (57.6) | <0.01 |
| Asthmab | 42 217.2 (17.6) | 39 287.0 (16.5) | 0.03 | 25 473.4 (11.2) | 25 401.5 (11.2) | <0.01 | 19 340.7 (11.7) | 19 599.7 (12.0) | <0.01 |
| Diabetes mellitusc | 3660.1 (1.5) | 3648.3 (1.5) | <0.01 | 3714.1 (1.6) | 3717.2 (1.6) | <0.01 | 2543.5 (1.5) | 2475.8 (1.5) | <0.01 |
| Chronic obstructive pulmonary disease | 1645.8 (0.7) | 1592.2 (0.7) | <0.01 | 1408.1 (0.6) | 1407.1 (0.6) | <0.01 | 989.6 (0.6) | 998.5 (0.6) | <0.01 |
| Cardiovascular disease | 2729.8 (1.1) | 2731.1 (1.1) | <0.01 | 2612.2 (1.1) | 2623.8 (1.2) | <0.01 | 1815.4 (1.1) | 1868.2 (1.1) | <0.01 |
| Cerebrovascular disease | 1997.8 (0.8) | 1995.6 (0.8) | <0.01 | 2017.1 (0.9) | 2023.2 (0.9) | <0.01 | 1409.6 (0.9) | 1446.4 (0.9) | <0.01 |
| Mental disease including dementia | 14 138.7 (5.9) | 14 021.8 (5.9) | <0.01 | 12 997.4 (5.7) | 13 009.7 (5.7) | <0.01 | 9484.1 (5.8) | 9453.6 (5.8) | <0.01 |
| Neurological disease | 16 233.3 (6.8) | 16 174.1 (6.8) | <0.01 | 16 372.8 (7.2) | 16 372.9 (7.2) | <0.01 | 11 597.8 (7.0) | 11 652.8 (7.1) | <0.01 |
| Anemia | 5062.0 (2.1) | 5154.8 (2.2) | <0.01 | 5179.3 (2.3) | 5170.0 (2.3) | <0.01 | 3538.4 (2.1) | 3549.1 (2.2) | <0.01 |
| Immune deficiency | 277.7 (0.1) | 268.6 (0.1) | <0.01 | 261.2 (0.1) | 259.2 (0.1) | <0.01 | 177.8 (0.1) | 198.1 (0.1) | <0.01 |
| Hepatic disease | 6912.4 (2.9) | 6930.9 (2.9) | <0.01 | 7078.3 (3.1) | 7081.3 (3.1) | <0.01 | 4849.3 (2.9) | 4781.4 (2.9) | <0.01 |
| Malignant tumor | 2446.5 (1.0) | 2423.1 (1.0) | <0.01 | 2526.7 (1.1) | 2529.7 (1.1) | <0.01 | 1742.1 (1.1) | 1638.3 (1.0) | <0.01 |
Data are n (%). Adjustment (standardization) was performed according to the inverse probability of treatment weighting method using a propensity score with each item as a covariate. SMD <0.1 indicated the characteristics were balanced between the comparison pairs.
Abbreviation: SMD, standardized mean difference.
aExcluding pneumonia
bDiagnosis based on administration of disease-related medication World Health Organization Anatomical Therapeutic Chemical Classification (WHO-ATC) code R03.
cDiagnosis based on administration of disease-related medication WHO-ATC code A10.